Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss
This news release highlights that a KFF analysis finds that 3.8 million Medicare beneficiaries met…
This news release highlights that a KFF analysis finds that 3.8 million Medicare beneficiaries met the criteria to be eligible for the new Medicare GLP-1 Bridge, based on claims data from 2023. The temporary program will provide coverage of three GLP-1 drugs used for weight reduction and weight management to eligible Medicare beneficiaries.
This policy watch discusses a recent Tennessee law that requires the sharing of data for applicants and/or enrollees for the state’s public assistance programs who do not have a qualified immigration status with immigration authorities, including for those enrolled in the state’s Children’s Special Services program, which serves children with disabilities.
Medicare has launched a temporary program covering GLP-1s for obesity for people with Medicare, known as the Medicare GLP-1 Bridge. This analysis estimates the number of Medicare Part D enrollees who could potentially qualify for the Bridge program by meeting all of the eligibility criteria, based on claims data from 2023.
The July 1 changes are being framed as student loan policy. But they raise a larger question about what kind of labor, and whose labor, America is willing to invest in. The post Federal Loan Policy Is Pricing Women Out of Healthcare’s Most Critical Roles appeared first on MedCity News.
Current AI tools often increase the disruption that radiologists already experience from using non-integrated platforms. The post Radiologists Need AI That Works Where They Work, Not Standalone Software appeared first on MedCity News.
We aren’t killing the problem that fax created. We are migrating it into a format that carries a higher expectation of automated processing — without yet having solved the underlying challenge that made automation hard in the first place. The post Don’t Celebrate the Wrong Win: What CMS-0053-F Actually Changes appeared first on MedCity News.
Alea Bates wasn’t ready to leave Tallahassee Memorial HealthCare’s main hospital four days after a stranger shot her seven times at close range. Miraculously, hospital records show, none of the bullets damaged her internal organs. But after surgery, Bates said, she couldn’t get out of bed or walk to the bathroom without help. She complained…
LADUE, Mo. — Over four consecutive days in January, Margaret Hvatum ran a 5K, a 10K, a half-marathon, and a full marathon. The 70-year-old covered a combined distance that’s nearly equivalent to running the length of Manhattan four times. By the end of the month, she was in a hospital bed. Hvatum, a part-time computer…
Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to Tepezza, an Amgen drug that had been the only approved therapy for this inflammatory eye disorder. The post FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen…
CMS is recalculating some 2026 Medicare Advantage Star Ratings after a court ruled it improperly calculated Clover Health’s rating, a decision that could boost payments for a small number of insurers. The post CMS Recalculates Star Ratings — Again appeared first on MedCity News.